Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 14, 2022.
While genetics are linked to gout diagnosis and lifestyle factors are related to risk, the association between healthy choices and risk mitigation remained unclear.
Rheumatoid arthritis is known risk factor for cardiovascular disease, but how much do you know about the association? Test your knowledge with this quiz.
After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.
Data from the POETYK PSO long-term extension (LTE) trial showed deucravacitinib was clinically effective and safe for treating adult patients with moderate-to-severe plaque psoriasis.
One-year results from the PsABio study provide evidence on factors that may impact treatment selection and decisions in clinical practice.